Recombinant oncotoxin AR209 (anti-p185(erbB-2)) diminishes human prostate carcinoma xenografts

Journal of Urology

Volumn 161, Issue 3, 1999, Pages 984-989

  Skrepnik, Nebojsa ^a   Zieske, Arthur W ^a   Bravo, Juan Carlos ^a   Gillespie, A Tod ^a   Hunt, Jay D ^a  

^a LOUISIANA STATE UNIV MEDICAL CENTER   (United States)

Author keywords

Adenocarcinoma; HER 2; Neu; Pseudomonas exotoxin A; Recombinant toxin

Indexed keywords

AR209; IMMUNOMODULATING AGENT; PSEUDOMONAS EXOTOXIN; UNCLASSIFIED DRUG;

ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ARTICLE; CONTROLLED STUDY; DRUG TARGETING; IMMUNOBLOTTING; IMMUNOTHERAPY; MALE; NONHUMAN; NUDE MOUSE; ONCOGENE NEU; PRIORITY JOURNAL; PROSTATE CARCINOMA; TUMOR VOLUME; XENOGRAFT;

EID: 0032853667     PISSN: 00225347     EISSN: None     Source Type: Journal    
DOI: 10.1016/S0022-5347(01)61833-0     Document Type: Article

References (38)

1. Cancer Facts and Figures-1997. Atlanta, GA: American Cancer Society, 1997.
2. Huncharek, M. and Muscat, J.: Genetic characteristics of prostate cancer. Cancer Epidemiol. Biomark. Prevent., 4: 681, 1995.
3. Carter, H. and Coffey, D.: The prostate: an increasing medical problem. Prostate, 16: 39, 1990.
4. Garnick, M. B.: Prostate cancer: screening, diagnosis, and management. Ann. Intern. Med., 118: 804, 1993.
5. Schellhammer, P. F., Kuban, D. A., and el-Mahdi, A. M.: Local failure after definitive radiation or surgical therapy for carcinoma of the prostate and options for prevention and therapy. Urol. Clin. North Am., 18: 495, 1991.
6. Huggins, C. and Hodges, C. V.: Studies on prostate cancer. I. The effect of castration, of estrogen and of androgen injection on serum phosphatases in metastatic carcinoma of the prostate. Cancer Res., 1: 293, 1941.
7. Torti, F. M. and Lum, B. L.: Chemotherapy in prostate cancer. In: Genitourinary Cancer. Contemporary Issues in Clinical Oncology. Edited by M. B. Garnick. New York: Churchill Livingstone, pp. 125-161, 1985.
8. Eisenberger, M. A., Simon, R., O'Dwyer, P. J., Wittes, R. E. and Friedmann, M. A.: A reevaluation of nonhormonal cytotoxic chemotherapy in the treatment of prostatic carcinoma. J. Clin. Oncol., 3: 827, 1985.
9. Tkaczuk, K., Eisenberger, M., Sinibaldi, V., Reyno, L., Jodrell, D. and Jacobs, S.: Activity of suramin in prostate cancer observed in a phase I trial. Proc. Am. Soc. Clin. Oncol., 11: 201, 1992 (Abstract).
10. Bogden, A. E., Taylor, J. E., Moreau, J. P. and Coy, D. H.: Treatment of R-3327 prostate tumors with a somatostatin analogue (somatuline) as adjuvant therapy following surgical castration. Cancer Res., 50: 2646, 1990.
11. Kasprzyk, P. G., Sullivan, T. L., Hunt, J. D., Gubish, C. T., Scoppa, C. A., Oelkuct, M., Bird, R., Fischer, P. H., Siegfried, J. M. and King, C. R.: Activity of anti-erbB-2 recombinant toxin OLX-209 on lung cancer cell lines in the absence of erbB-2 gene amplification. Clin. Cancer Res., 2: 75, 1996.
12. Batra, J. K., Kasprzyk, P. G., Bird, R. E., Pastan, I. and King, C. R.: Recombinant anti-erbB-2 immunotoxins containing Pseudomonas exotoxin. Proc. Natl. Acad. Sci. USA, 89: 5867, 1992.
13. neu) in human non-small cell carcinomas of the lung. Cancer Res., 50: 421, 1990.
14. Shi, D., He, G., Cao, S., Pan, W., Zhang, H-Z., Yu, D. and Hung, M-C.: Overexpression of the c-erbB-2/neu-encoded p185 protein in primary lung cancer. Mol. Carcinogen., 5: 213, 1992.
15. Correa, P., Haenszel, W., Cuello, C., Arder, M. and Tannenbaum, S. R.: A model for gastric cancer epidemilogy. Lancet, 2: 58, 1975.
16. Slamon, D. J., Godolphin, W., Jones, L. A., Holt, J. A., Wong, S. G., Keith, D. E., Levin, W. J., Stuart, S. G., Udove, J., Ullrich, A. and Press, M. F.: Studies of the Her-2/neu protooncogene in human breast and ovarian cancer. Science, 244: 707, 1989.
17. Zhau, H. E., Wan, D. S. and Zhou, J.: Expression of c-erb B-2/neu protoonocogene in human prostatic cancer tissues and cell lines. Mol. Carcinogen., 5: 320, 1992.
18. Zhau, H. E., Pisters, L. L., Hall, C., Zhao, L. S., Troncoso, P., Pollack, A. and Chung, L. W. K.: Biomarkers associated with prostate cancer progression. J. Cell. Biochem., 19(Supplement): 208, 1994 .
19. Netto, G. J. and Humphrey, P. A.: Molecular biologic aspects of human prostatic carcinoma. Am. J. Clin. Pathol., 102(Suppl. 1): S57, 1994.
20. Grizzle, W. E., Myers, R. B., Arnold, M. M. and Srivastava, S.: Evaluation of biomarkers in breast and prostate cancer. J. Cell Biol., 19(Supplement): 259, 1994.
21. Bostwick, D. G., Burke, H. B., Wheeler, T. M., Chung, L. W. K., Bookstein, R., Pretlow, T. G., Nagle, R. B., Montironi, R., Lieber, M. M., Veltri, R. W., Grizzle, W. E. and Grignon, D. J.: The most promising surrogate endpoint biomarkers for screening candidate chemopreventive compounds for prostatic adenocarcinoma in short-term phase II clinical trials. J. Cell Biol., 19(Supplement): 283, 1994.
22. Bostwick, D. G. and Qian, J.: Current and proposed biologic markers in prostate cancer: 1994. J. Cell Biol., 19(Supplement): 197, 1994.
23. erbB-2 specific single- chain antibody toxins differ in their cell-killing activity on tumor cells expressing both receptor proteins. Int. J. Cancer, 60: 1377, 1995.
24. Skrepnik, N., Araya, J. C., Qian, Z., Xu, H., Hamide, J., Mera, R. and Hunt, J. D.: Effects of anti-erbB-2 (HER-2/neu) recombinant oncotoxin AR209 on human non-small cell lung carcinoma grown orthotopically in athymic nude mice. Clin. Cancer Res., 2: 1851, 1996.
25. Horoszewicz, J. S., Leong, S. S., Chu, T. M., Wajsman, Z. L., Friedman, M., Papsidero, L., Kim, U., Chai, L. S., Kakati, S., Arya, S. and Sandberg, A. A.: The LNCaP cell line-a new model for studies on human prostatic carcinoma. In: Models for Prostate Cancer. Edited by G. P. Murphy. New York: Alan R. Liss, Inc., pp. 115-132, 1980.
26. Kaighn, M. E., Lechner, J. F., Babcock, M. S., Marnell, M., Ohnuki, Y. and Narayan, K. S.: The Pasdena cell lines. In: Models for Prostate Cancer. Edited by G. P. Murphy. New York: Alan R. Liss, Inc., pp. 85-109, 1980.
27. Mickey, D. D., Stone, K. R., Wunderli, H., Mickey, G. H. and Paulson, D. F.: Characterization of human prostate adenocarcinoma cell line (DU 145) as a monolayer culture and as a solid tumor in athymic mice. In Models for Prostate Cancer. Edited by G. P. Murphy. New York: Alan R. Liss, Inc., pp. 67-84, 1980.
28. Weiner, L. M., O'Dwyer, J., Kitson, J., Comis, R. L., Frankel, A. E., Bauer, R. J., Konrad, M. S. and Groves, E. S.: Phase I evaluation of an anti-breast carcinoma monoclonal antibody 260F9-recombinant ricin A chain immunoconjugate. Cancer Res., 49: 4062, 1989.
29. Lynch, T. J., Jr.: Immunotoxin therapy of small cell lung cancer. N901-blocked ricin for relapsed small cell lung cancer. Chest, 103: 4365, 1993.
30. Grossbard, M. L., Lambert, J. M., Goldmacher, U. S., Spector, N. L., Kinsella, J., Eliseo, L., Coral, F., Taylor, J. A., Blattler, W. A. and Epstein, C. L.: Anti-B4-blocked ricin: a phase I trial of 7-day continuous infusion in patients with B-cell neoplasms. J. Clin. Oncol., 11: 726, 1993.
31. Grossbard, M. L., Gribben, J. G., Freedman, A. S., Lambert, J. M., Kinsella, J., Rabinowe, S. N., Eliseo, L., Taylor, J. A., Blattler, W. A. and Epstein, C. L.: Adjuvant immunotoxin therapy with anti-B4-blocked ricin after autologous bone marrow transplantation for patients with B-cell non-Hodgkin's lymphoma. Blood, 81: 2263, 1993.
32. Sadasivan, R., Morgan, R. and Hennings, S.: Overexpression of Her-2/neu may be an indicator of poor prognosis in prostate cancer. J. Urol., 150: 126, 1993.
33. Blumenthal, R. D., Stein, R., Sharkey, R. M., Goldenberg, D. M., Ong, G. L., Klein, K. M. and Mattes, M. J.: Antibody penetration of tumor GS-7 xenografts in nude mice: a model for mucinous adenocarcinoma of the colon. Cancer Res., 56: 3508, 1996.
34. Sung, C., Dedrick, R. L., Hall, W. A., Johnson, P. A. and Youle, R. J.: The spatial distribution of immunotoxins in solid tumors: assessment by quantitative autoradiography. Cancer Res., 53: 2092, 1993.
35. Rippley, R. K. and Stokes, C. L.: Effects of cellular pharmacology on drug distribution in tissues. Biophys. J., 69: 825, 1995.
36. Freeman, S. M., Abbound, C. N., Whartenby, K. A., Packman, C. H., Koeplin, D. S., Moolten, F. L. and Abraham, G. N. The "Bystander Effect": tumor regression when a fraction of the tumor mass is genetically modified. Cancer Res., 53: 5274, 1993.
37. Hoganson, D. K., Batra, R. K., Olsen, J. C. and Boucher, R. C.: Comparison of the effects of three different toxin genes and their levels of expression on cell growth and bystander effect in lung adenocarcinoma. Cancer Res., 56: 1315, 1996.
38. Reiter, Y., Brinkmann, U., Jung, S. H., Lee, B., Kasprzyk, P. G., King, C. R. and Pastan, I.: Improved binding and antitumor activity of a recombinant anti-erbB2 immunotoxin by disulfide stabilization of the Fv fragment. J. Biol. Chem., 269: 18327, 1994.